While lifestyle alterations have been previously recommended to control potassium levels for some patients with hyperkalemia, ...

Finerenone use in trial patients with HFpEF or HFmrEF increased hyperkalemia risk, especially in those with CKD. Finerenone use in patients with heart failure and preserved or mildly reduced ejection ...

A real-world study finds reduced RAASi-related hyperkalemia risk among at-risk patients initiating SGLT2 inhibitors. Sodium glucose cotransporter 2 inhibitor (SGLT2i) use is associated with lower ...

Please provide your email address to receive an email when new articles are posted on . Patients with a urine albumin-creatinine ratio of at least 3,500 mg/g had high rates of hyperkalemia. High rates ...

Hyperkalemia, defined as a serum potassium concentration above 5.0 mmol/L, is a frequent and potentially life-threatening complication of chronic kidney disease (CKD). As glomerular filtration rate ...

A series of major studies has shown that finerenone preserves kidney function, reduces cardiovascular risk, and improves survival across a much broader range of patients with chronic kidney disease ...

A new risk model may help identify which patients with chronic kidney disease (CKD) and diabetes are more likely to develop hyperkalemia, granting physicians more confidence in prescribing medications ...

The leading causes of hyperkalemia are chronic kidney disease, uncontrolled diabetes, dehydration, an injury causing severe bleeding, consuming excessive dietary potassium, and some medications. A ...

Finerenone also reduced albuminuria at month 12 by 42% and lowered the risk of kidney failure or an eGFR decline of 40% or ...

Bayer announced today full results from the Phase III FIND-CKD trial investigating KERENDIA ® (finerenone) in adults with non-diabetic chronic kidney disease (nd-CKD) who were also receiving ...

You should limit sodium to less than 2,300 milligrams daily to decrease fluid retention and blood pressure. Eat no more than ...